Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
26 April 2023 - 10:01PM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced the
appointment of Nancy Valente, M.D., to Executive Vice President,
Chief Development Officer. Dr. Valente has more than 20 years of
experience in late-stage biopharmaceutical product development, and
she most recently served as a senior vice president at Genentech, a
member of the Roche Group, and as its global head and co-lead of
global product development of its oncology and hematology
therapeutic area.
Dr. Valente has served as an independent member of Xencor’s
Board of Directors since September 2022, a role from which she has
resigned. In her new role, effective May 1, 2023, she will be
responsible for leading Xencor’s clinical and medical strategy and
execution. Allen Yang, M.D., Ph.D., Chief Medical Officer, will
continue to advise the Company and after a transition period will
leave Xencor to pursue other opportunities.
“During her time on our Board, Nancy gained a deep understanding
of our XmAb® platforms, portfolio strategy, development programs,
and people, and we are delighted that she has chosen to join our
senior management team,” said Bassil Dahiyat, Ph.D., President and
Chief Executive Officer at Xencor. “Dr. Valente brings very broad
drug development expertise with multiple commercial successes over
her career. Her depth of experience will be a great benefit, as we
seek to efficiently and aggressively develop our clinical pipeline,
rapidly advance to proof-of-concept decisions, and ultimately
deliver life-saving medicines to patients. We would also like to
thank Allen Yang for his many contributions to Xencor, particularly
building a new clinical leadership team, overseeing multiple study
initiations, and leading our clinical organization through the
pandemic.”
“Xencor has a remarkably productive, world-class biologics
discovery team that has stayed at the cutting edge of protein
engineering to create drug candidates with novel mechanisms. A
commercially focused clinical strategy will enable us to advance
these molecules rapidly in settings that can benefit the most
patients with the greatest needs,” said Dr. Valente. “In my time on
the Board, I have enjoyed advising the company’s R&D
organization and now look forward to working side-by-side with
Xencor’s talented scientists and physicians to create high-impact
therapeutics.”
In her most recent role at Genentech, Dr. Valente was
responsible for strategic planning, clinical development, and
collaboration activities in the areas of oncology and hematology
product development, playing a critical role in the development and
approvals of new therapies for patients with serious illnesses,
including GAZYVA®, VENCLEXTA®, POLIVY® and HEMLIBRA®. Dr. Valente
has held various positions with increasing responsibilities at
Genentech and then at Roche after Genentech was acquired by Roche,
including vice president for global product development for
oncology, hematology franchise and senior group medical director,
leader for hematology development. Before Genentech, she served in
senior-level positions at Anosys, Inc. and Coulter Pharmaceutical,
Inc., and earlier in her career, she held academic positions at the
University of California, San Francisco (UCSF). Dr. Valente
received her M.D. from the University of Missouri and completed her
internal medicine training at Oregon Health & Science
University, followed by fellowships in hematology at Stanford
University and oncology at UCSF.
GAZYVA and POLIVY are registered trademarks of Genentech, Inc.
HEMLIBRA is a registered trademark of Chugai Pharmaceutical Co.,
Ltd. VENCLEXTA is a registered trademark of AbbVie Inc.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
proteins structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to, statements regarding Xencor’s clinical portfolio,
research and development programs, the quotations from Xencor's
President and Chief Executive Officer and independent Board member
and other statements that are not purely statements of historical
fact. Such statements are made on the basis of the current beliefs,
expectations, and assumptions of the management of Xencor and are
subject to significant known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements and the timing of events to be materially different
from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance
or results. Such risks include, without limitation, the risks
associated with the process of discovering, developing,
manufacturing and commercializing drugs that are safe and effective
for use as human therapeutics and other risks, including the
ability of publicly disclosed preliminary clinical trial data to
support continued clinical development and regulatory approval for
specific treatments, in each case as described in Xencor's public
securities filings. For a discussion of these and other factors,
please refer to Xencor's annual report on Form 10-K for the year
ended December 31, 2022, as well as Xencor's subsequent filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, as amended to date. All forward-looking statements are
qualified in their entirety by this cautionary statement and Xencor
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005440/en/
Charles Liles cliles@xencor.com (626) 737-8118 Jason I. Spark
Evoke Canale jason.spark@evokegroup.com (619) 849-6005
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2024 to Mar 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2023 to Mar 2024